OS Therapies Incorporated ( (OSTX) ) has released a notification of late filing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OS Therapies Incorporated has filed a Form 12b-25 notifying investors of a delayed Quarterly Report on Form 10-Q (Quarter Report) for the period ended March 31, 2026. The company’s late filing relates specifically to this Form 10-Q (Quarter Report) and does not affect any other periodic reports.
Management cites delays in compiling and reviewing information needed to complete the financial statement close process as the main cause. The company states that filing on time would have required unreasonable effort or expense, but it does not mention auditor changes, control failures, or external investigations.
OS Therapies plans to submit the Form 10-Q (Quarter Report) within the standard five-calendar-day extension window allowed under SEC Rule 12b-25. This implies investors should expect the quarterly report to be filed no later than May 20, 2026, assuming no further complications.
The company confirms that all other required SEC reports over the past 12 months have been filed. It also indicates that it does not expect any significant change in results of operations versus the same quarter last year, though investors should remember that such statements are forward-looking and subject to revision.
OS Therapies emphasizes its intent to remain compliant with SEC reporting rules while it completes the quarter-end close process. The notification is signed by Chief Executive Officer Paul Romness on May 15, 2026, underscoring executive-level oversight of the delayed Form 10-Q (Quarter Report).
The most recent analyst rating on (OSTX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.
Spark’s Take on OSTX Stock
According to Spark, TipRanks’ AI Analyst, OSTX is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, widening losses, and elevated cash burn), partially offset by a cleaner balance sheet (positive equity and no reported debt). Technicals show improving near-term momentum, and corporate updates are supportive due to regulatory progress and added funding, but valuation remains pressured by ongoing losses and no dividend support.
To see Spark’s full report on OSTX stock, click here.
More about OS Therapies Incorporated
Average Trading Volume: 612,496
Technical Sentiment Signal: Buy
Current Market Cap: $79.03M
Find detailed analytics on OSTX stock on TipRanks’ Stock Analysis page.